Patient Reported Symptoms in Ovarian Cancer (PRECISION)
NCT ID: NCT01422265
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
56 participants
OBSERVATIONAL
2011-06-30
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* This must be the first recurrence of the epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma
* Are at least two weeks but no more than 3 months after the completion of second-line cytotoxic chemotherapy
* Are currently under observation or being treated with bevacizumab as a second-line maintenance therapy
* Have a valid email address and access to the internet
* Provide voluntary written informed consent
* Speak and read English fluently
Exclusion Criteria
* Another primary diagnosis of cancer in a different site
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genentech, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Genentech, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Goodyear, Arizona, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
Salinas, California, United States
Whittier, California, United States
Englewood, Colorado, United States
Farmington, Connecticut, United States
New Britain, Connecticut, United States
Augusta, Georgia, United States
Hinsdale, Illinois, United States
Joliet, Illinois, United States
Skokie, Illinois, United States
Indianapolis, Indiana, United States
Indianapolis, Indiana, United States
Baltimore, Maryland, United States
Cumberland, Maryland, United States
Missoula, Montana, United States
Lincoln, Nebraska, United States
Buffalo, New York, United States
New York, New York, United States
Watertown, New York, United States
Canton, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Oklahoma City, Oklahoma, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Chattanooga, Tennessee, United States
Salt Lake City, Utah, United States
Annandale, Virginia, United States
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
130/070
Identifier Type: OTHER
Identifier Source: secondary_id
ML28066
Identifier Type: -
Identifier Source: org_study_id